Call for Abstract/Acceptance Result
Acceptance Result
Abstract Submission ID order
Session order
Abstract Submission Deadline
Noon, July 14 (THU), 2022 (JST)
Abstract submission has been closed. Thank you for your submitting.
Presenter Eligibility
The presenter must be a member of The Japanese Society for AIDS Research. If you are not a member of The Japanese Society for AIDS Research, please review the below "this page" and complete your membership. However, the co-author(s) does not have to be The Japanese Society for AIDS Research member(s).
Only one presentation is allowed per person. However, this may not apply to co-authors listed in the joint presentation.
Please review this page
The Japanese Society for AIDS Research Secretariat
Microbiological Science Inc.
4-13-18 Koishikawa, Bunkyo-ku, Tokyo
112-0002, Japan
Fax: +81-3-6231-4035
E-mail: biseibutsu-com@umin.ac.jp
Type of Presentation
We are calling for two types of presentation for the general session: Oral and Poster.
The Program Committee will, choose oral presenters from the abstracts submitted under the types "Oral" or "Either".
If you would like to give an oral presentation, please choose for Oral Presentation.
If you would like to give a poster presentation, please choose for Poster.
There will be a workshop held with excellent abstracts, selected from [Clinical] and [Basic] category, that are submitted by young participants.
*Criterion of "young participant" is first authors being younger than 45 years old as of December 1, 2022, and is a member of The Japanese Society for AIDS Research
*Details will be announced at later date.
Category
| ＜clinical＞ | |
|---|---|
| 1. opportunistic infection / malignancy / hepatitis | 11. U=U and safer conception /mother-to-child transmission / dentistry |
| 2. anti-retroviral therapy | 12. laboratory test |
| 3. aging / elderly health | 13. clinical epidemiology |
| 4. lifestyle disease | 14. nursing / long-term care / collaborativecare |
| 5. weight gain / adverse drug reaction | 15. case report |
| 6. HAND / mental health / drug addiction | 16. SNS / communication |
| 7. clinical pharmacology | 17. international cooperation |
| 8. drug resistance (clinical) | 18. COVID-19 : online care / collaborative |
| 9. pharmacist / pharmacy / medicationadherence | 19. COVID-19 : acute infection / co-infection |
| 10. PEP / PrEP / STI / STD | 20. others (clinical) |
| ＜basic＞ | |
|---|---|
| 1. replication / infection | 8. drug resistance (basic) |
| 2. host factor | 9. molecular epidemiology |
| 3. accessory gene | 10. structure |
| 4. pathogenesis | 11. latent infection / reservoir |
| 5. immunity / vaccine | 12. HTLV-1 & other retroviruses |
| 6. animal model | 13. COVID-19 (basic) |
| 7. development of anti-retrovirals | 14. others (basic) |
| ＜social＞ | |
|---|---|
| 1. epidemiology | 11. policy / medical system |
| 2. behavioral science / opinionnaire | 12. HIV testing & consultation |
| 3. education | 13. counseling |
| 4. prevention / condom / PrEP | 14. social work |
| 5. MSM | 15. support for people living with HIV |
| 6. foreign resident | 16. health & care consultation |
| 7. global health | 17. home care support / care coordination |
| 8. sex work | 18. human rights / ethics / U=U |
| 9. substance use / addiction | 19. information provision |
| 10. drug-induced HIV infection | 20. others (social) |
Presentation Title Character Limit
The title should be no longer than 160 characters (including spaces).
Superscripts, subscripts, and italics are available, but not line breaks.
Abstract Character Limit
The abstract main text should be no longer than 1,600 characters (including spaces).
Acceptance and Classification
The Program Committee is in sole charge of the decision of acceptance or rejection of the abstracts. The decision will be communicated through email.
Abstract Submission Method
After submitting the abstract, you will receive an E-mail confirming the receipt of your abstract.
If you do not receive this e-mail, please contact the congress secretariat.
(aids36@sunpla-mcv.com)
Abstract SubmissionReference / Update
Personal Information Policy
Personal information submitted will only be used for the purpose of conducting The 36th Annual Meeting of the Japanese Society for AIDS Research Meeting. Moreover, personal information submitted will be strictly controlled with a necessary security measure.
Disclosure of Conflict of Interest (COI)
Disclosure of conflict of interest (COI) is required for all the presentation.
Please click on the button below to download COI slide sample.
Conflict of Interest No Conflict of Interest
Congress Secretariat
Sunplanet Co., Ltd.
E-mail: aids36@sunpla-mcv.com